Nuclear transport of galectin-3 and its therapeutic implications

Seminars in Cancer Biology

Volumn 27, Issue , 2014, Pages 30-38

  Funasaka, Tatsuyoshi ^a   Raz, Avraham ^b   Nangia Makker, Pratima ^b,c  

^a Nanzando Pharmacies Co   (Japan)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c John D Dingell VA Medical Centre   (United States)

Author keywords

Beta catenin; Galectin 3; Nuclear cytoplasmic transport

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BETA CATENIN; BORTEZOMIB; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; GALECTIN 3; GEMCITABINE; GLYCOGEN SYNTHASE KINASE 3BETA; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; NUCLEOPORIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESEARCH; CANCER RESISTANCE; CELLULAR DISTRIBUTION; CHROMOSOME TRANSLOCATION; DRUG CYTOTOXICITY; DRUG TARGETING; GENE MUTATION; GENE SILENCING; HUMAN; MOLECULAR DYNAMICS; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEAR PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; GALECTIN 3; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NUCLEAR PORE COMPLEX PROTEINS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84904460315     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.03.004     Document Type: Review

References (158)

1. Barondes S.H., Cooper D.N., Gitt M.A., Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994, 269(33):20807-20810.
2. Hirabayashi J., Hashidate T., Arata Y., Nishi N., Nakamura T., Hirashima M., et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002, 1572(2-3):232-254.
3. Davidson P.J., Li S.Y., Lohse A.G., Vandergaast R., Verde E., Pearson A., et al. Transport of galectin-3 between the nucleus and cytoplasm. I. Conditions and signals for nuclear import. Glycobiology 2006, 16(7):602-611.
4. Li S.Y., Davidson P.J., Lin N.Y., Patterson R.J., Wang J.L., Arnoys E.J. Transport of galectin-3 between the nucleus and cytoplasm. II. Identification of the signal for nuclear export. Glycobiology 2006, 16(7):612-622.
5. Davidson P.J., Davis M.J., Patterson R.J., Ripoche M.A., Poirier F., Wang J.L. Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 2002, 12(5):329-337.
6. Hughes R.C. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1999, 1473(1):172-185.
7. Nickel W. Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells. Traffic 2005, 6(8):607-614.
8. Sato S., Hughes R.C. Control of Mac-2 surface expression on murine macrophage cell lines. Eur J Immunol 1994, 24(1):216-221.
9. Lindstedt R., Apodaca G., Barondes S.H., Mostov K.E., Leffler H. Apical secretion of a cytosolic protein by Madin-Darby canine kidney cells. Evidence for polarized release of an endogenous lectin by a nonclassical secretory pathway. J Biol Chem 1993, 268(16):11750-11757.
10. Sato S., Burdett I., Hughes R.C. Secretion of the baby hamster kidney 30-kDa galactose-binding lectin from polarized and nonpolarized cells: a pathway independent of the endoplasmic reticulum-Golgi complex. Exp Cell Res 1993, 207(1):8-18.
11. Mehul B., Hughes R.C. Plasma membrane targetting, vesicular budding and release of galectin 3 from the cytoplasm of mammalian cells during secretion. J Cell Sci 1997, 110(Pt 10):1169-1178.
12. Thery C., Boussac M., Veron P., Ricciardi-Castagnoli P., Raposo G., Garin J., et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2001, 166(12):7309-7318.
13. Baptiste T.A., James A., Saria M., Ochieng J. Mechano-transduction mediated secretion and uptake of galectin-3 in breast carcinoma cells: implications in the extracellular functions of the lectin. Exp Cell Res 2007, 313(4):652-664.
14. Boscher C., Dennis J.W., Nabi I.R. Glycosylation, galectins and cellular signaling. Curr Opin Cell Biol 2011, 23(4):383-392.
15. Di Lella S., Sundblad V., Cerliani J.P., Guardia C.M., Estrin D.A., Vasta G.R., et al. When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry 2011, 50(37):7842-7857.
16. Lau K.S., Dennis J.W. N-Glycans in cancer progression. Glycobiology 2008, 18(10):750-760.
17. van Kooyk Y., Rabinovich G.A. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol 2008, 9(6):593-601.
18. Rabinovich G.A., Ilarregui J.M. Conveying glycan information into T-cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments. Immunol Rev 2009, 230(1):144-159.
19. Cedeno-Laurent F., Opperman M.J., Barthel S.R., Hays D., Schatton T., Zhan Q., et al. Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J Invest Dermatol 2012, 132(2):410-420.
20. Lagana A., Goetz J.G., Cheung P., Raz A., Dennis J.W., Nabi I.R. Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells. Mol Cell Biol 2006, 26(8):3181-3193.
21. Markowska A.I., Liu F.T., Panjwani N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med 2010, 207(9):1981-1993.
22. Merlin J., Stechly L., de Beauce S., Monte D., Leteurtre E., van Seuningen I., et al. Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene 2011, 30(22):2514-2525.
23. Nangia-Makker P., Honjo Y., Sarvis R., Akahani S., Hogan V., Pienta K.J., et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000, 156(3):899-909.
24. Haudek K.C., Patterson R.J., Wang J.L. SR proteins and galectins: what's in a name?. Glycobiology 2010, 20(10):1199-1207.
25. Park J.W., Voss P.G., Grabski S., Wang J.L., Patterson R.J. Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein. Nucl Acids Res 2001, 29(17):3595-3602.
26. van den Brule F.A., Waltregny D., Liu F.T., Castronovo V. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000, 89(4):361-367.
27. Yu F., Finley R.L., Raz A., Kim H.R. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 2002, 277(18):15819-15827.
28. Yoshii T., Fukumori T., Honjo Y., Inohara H., Kim H.R., Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002, 277(9):6852-6857.
29. Honjo Y., Inohara H., Akahani S., Yoshii T., Takenaka Y., Yoshida J., et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 2000, 6(12):4635-4640.
30. Califice S., Castronovo V., Bracke M., van den Brule F. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 2004, 23(45):7527-7536.
31. Califice S., Castronovo V., Van Den Brule F. Galectin-3 and cancer (Review). Int J Oncol 2004, 25(4):983-992.
32. Moisa A., Fritz P., Eck A., Wehner H.D., Murdter T., Simon W., et al. Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer. Anticancer Res 2007, 27(4B):2131-2139.
33. Shekhar M.P., Nangia-Makker P., Tait L., Miller F., Raz A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol 2004, 165(6):1931-1941.
34. Sanjuan X., Fernandez P.L., Castells A., Castronovo V., van den Brule F., Liu F.T., et al. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression [see comments]. Gastroenterology 1997, 113(6):1906-1915.
35. Akahani S., Nangia-Makker P., Inohara H., Kim H.R., Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997, 57(23):5272-5276.
36. Yang R.Y., Hsu D.K., Liu F.T. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 1996, 93(13):6737-6742.
37. Fukumori T., Takenaka Y., Oka N., Yoshii T., Hogan V., Inohara H., et al. Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res 2004, 64(10):3376-3379.
38. Liu L., Sakai T., Sano N., Fukui K. Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling. Biochem J 2004, 380(Pt 1):31-41.
39. Liu F.T., Patterson R.J., Wang J.L. Intracellular functions of galectins. Biochim Biophys Acta 2002, 1572(2-3):263-273.
40. Matarrese P., Fusco O., Tinari N., Natoli C., Liu F.T., Semeraro M.L., et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 2000, 85(4):545-554.
41. Elad-Sfadia G., Haklai R., Balan E., Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 2004, 279(33):34922-34930.
42. Shalom-Feuerstein R., Cooks T., Raz A., Kloog Y. Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. Cancer Res 2005, 65(16):7292-7300.
43. Lee Y.J., Song Y.K., Song J.J., Siervo-Sassi R.R., Kim H.R., Li L., et al. Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt. Exp Cell Res 2003, 288(1):21-34.
44. Oka N., Nakahara S., Takenaka Y., Fukumori T., Hogan V., Kanayama H.O., et al. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res 2005, 65(17):7546-7553.
45. Gruenbaum Y., Margalit A., Goldman R.D., Shumaker D.K., Wilson K.L. The nuclear lamina comes of age. Nat Rev Mol Cell Biol 2005, 6(1):21-31.
46. Dechat T., Pfleghaar K., Sengupta K., Shimi T., Shumaker D.K., Solimando L., et al. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev 2008, 22(7):832-853.
47. Voeltz G.K., Rolls M.M., Rapoport T.A. Structural organization of the endoplasmic reticulum. EMBO Rep 2002, 3(10):944-950.
48. Vasu S.K., Forbes D.J. Nuclear pores and nuclear assembly. Curr Opin Cell Biol 2001, 13(3):363-375.
49. Meinema A.C., Poolman B., Veenhoff L.M. The transport of integral membrane proteins across the nuclear pore complex. Nucleus 2012, 3(4):322-329.
50. Gorlich D., Kutay U. Transport between the cell nucleus and the cytoplasm. Annu Rev Cell Dev Biol 1999, 15:607-660.
51. Tran E.J., Wente S.R. Dynamic nuclear pore complexes: life on the edge. Cell 2006, 125(6):1041-1053.
52. Mohr D., Frey S., Fischer T., Guttler T., Gorlich D. Characterisation of the passive permeability barrier of nuclear pore complexes. EMBO J 2009, 28(17):2541-2553.
53. Yang Q., Rout M.P., Akey C.W. Three-dimensional architecture of the isolated yeast nuclear pore complex: functional and evolutionary implications. Mol Cell 1998, 1(2):223-234.
54. Suntharalingam M., Wente S.R. Peering through the pore: nuclear pore complex structure, assembly, and function. Dev Cell 2003, 4(6):775-789.
55. Schermelleh L., Carlton P.M., Haase S., Shao L., Winoto L., Kner P., et al. Subdiffraction multicolor imaging of the nuclear periphery with 3D structured illumination microscopy. Science 2008, 320(5881):1332-1336.
56. Cronshaw J.M., Krutchinsky A.N., Zhang W., Chait B.T., Matunis M.J. Proteomic analysis of the mammalian nuclear pore complex. J Cell Biol 2002, 158(5):915-927.
57. Schwartz T.U. Modularity within the architecture of the nuclear pore complex. Curr Opin Struct Biol 2005, 15(2):221-226.
58. Alber F., Dokudovskaya S., Veenhoff L.M., Zhang W., Kipper J., Devos D., et al. The molecular architecture of the nuclear pore complex. Nature 2007, 450(7170):695-701.
59. Capelson M., Hetzer M.W. The role of nuclear pores in gene regulation, development and disease. EMBO Rep 2009, 10(7):697-705.
60. Chook Y.M., Blobel G. Karyopherins and nuclear import. Curr Opin Struct Biol 2001, 11(6):703-715.
61. Mosammaparast N., Pemberton L.F. Karyopherins: from nuclear-transport mediators to nuclear-function regulators. Trends Cell Biol 2004, 14(10):547-556.
62. Pemberton L.F., Paschal B.M. Mechanisms of receptor-mediated nuclear import and nuclear export. Traffic 2005, 6(3):187-198.
63. Kau T.R., Way J.C., Silver P.A. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004, 4(2):106-117.
64. Dauer W.T., Worman H.J. The nuclear envelope as a signaling node in development and disease. Dev Cell 2009, 17(5):626-638.
65. D'Angelo M.A., Gomez-Cavazos J.S., Mei A., Lackner D.H., Hetzer M.W. A change in nuclear pore complex composition regulates cell differentiation. Dev Cell 2012, 22(2):446-458.
66. Lupu F., Alves A., Anderson K., Doye V., Lacy E. Nuclear pore composition regulates neural stem/progenitor cell differentiation in the mouse embryo. Dev Cell 2008, 14(6):831-842.
67. Zhang X., Chen S., Yoo S., Chakrabarti S., Zhang T., Ke T., et al. Mutation in nuclear pore component NUP155 leads to atrial fibrillation and early sudden cardiac death. Cell 2008, 135(6):1017-1027.
68. Basel-Vanagaite L., Muncher L., Straussberg R., Pasmanik-Chor M., Yahav M., Rainshtein L., et al. Mutated nup62 causes autosomal recessive infantile bilateral striatal necrosis. Ann Neurol 2006, 60(2):214-222.
69. Enninga J., Levy D.E., Blobel G., Fontoura B.M. Role of nucleoporin induction in releasing an mRNA nuclear export block. Science 2002, 295(5559):1523-1525.
70. Wu X., Kasper L.H., Mantcheva R.T., Mantchev G.T., Springett M.J., van Deursen J.M. Disruption of the FG nucleoporin NUP98 causes selective changes in nuclear pore complex stoichiometry and function. Proc Natl Acad Sci U S A 2001, 98(6):3191-3196.
71. Asally M., Yasuda Y., Oka M., Otsuka S., Yoshimura S.H., Takeyasu K., et al. Nup358, a nucleoporin, functions as a key determinant of the nuclear pore complex structure remodeling during skeletal myogenesis. FEBS J 2011, 278(4):610-621.
72. Dawlaty M.M., Malureanu L., Jeganathan K.B., Kao E., Sustmann C., Tahk S., et al. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell 2008, 133(1):103-115.
73. Pichler A., Gast A., Seeler J.S., Dejean A., Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 2002, 108(1):109-120.
74. Zhang H., Saitoh H., Matunis M.J. Enzymes of the SUMO modification pathway localize to filaments of the nuclear pore complex. Mol Cell Biol 2002, 22(18):6498-6508.
75. Martinez N., Alonso A., Moragues M.D., Ponton J., Schneider J. The nuclear pore complex protein Nup88 is overexpressed in tumor cells. Cancer Res 1999, 59(21):5408-5411.
76. Gould V.E., Martinez N., Orucevic A., Schneider J., Alonso A. A novel, nuclear pore-associated, widely distributed molecule overexpressed in oncogenesis and development. Am J Pathol 2000, 157(5):1605-1613.
77. Agudo D., Gomez-Esquer F., Martinez-Arribas F., Nunez-Villar M.J., Pollan M., Schneider J. Nup88 mRNA overexpression is associated with high aggressiveness of breast cancer. Int J Cancer 2004, 109(5):717-720.
78. Lu Y., Lemon W., Liu P.Y., Yi Y., Morrison C., Yang P., et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006, 3(12):e467.
79. Kao J., Salari K., Bocanegra M., Choi Y.L., Girard L., Gandhi J., et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009, 4(7):e6146.
80. Gough S.M., Slape C.I., Aplan P.D. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood 2011, 118(24):6247-6257.
81. Funasaka T., Wong R.W. The role of nuclear pore complex in tumor microenvironment and metastasis. Cancer Metastasis Rev 2011, 30(2):239-251.
82. Graux C., Cools J., Melotte C., Quentmeier H., Ferrando A., Levine R., et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36(10):1084-1089.
83. Funasaka T., Tsuka E., Wong R.W. Regulation of autophagy by nucleoporin Tpr. Scientific Rep 2012, 2:878.
84. Nakano H., Funasaka T., Hashizume C., Wong R.W. Nucleoporin translocated promoter region (Tpr) associates with dynein complex, preventing chromosome lagging formation during mitosis. J Biol Chem 2010, 285(14):10841-10849.
85. Funasaka T., Nakano H., Wu Y., Hashizume C., Gu L., Nakamura T., et al. RNA export factor RAE1 contributes to NUP98-HOXA9-mediated leukemogenesis. Cell Cycle 2011, 10(9):1456-1467.
86. Imamoto N., Funakoshi T. Nuclear pore dynamics during the cell cycle. Curr Opin Cell Biol 2012, 24(4):453-459.
87. Takenaka Y., Fukumori T., Raz A. Galectin-3 and metastasis. Glycoconj J 2004, 19(7-9):543-549.
88. Liu F.T., Rabinovich G.A. Galectins as modulators of tumour progression. Nat Rev Cancer 2005, 5(1):29-41.
89. Dumic J., Dabelic S., Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006, 1760(4):616-635.
90. Dagher S.F., Wang J.L., Patterson R.J. Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci U S A 1995, 92(4):1213-1217.
91. Lin H.M., Pestell R.G., Raz A., Kim H.R. Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene 2002, 21(52):8001-8010.
92. Shimura T., Takenaka Y., Tsutsumi S., Hogan V., Kikuchi A., Raz A. Galectin-3, a novel binding partner of beta-catenin. Cancer Res 2004, 64(18):6363-6367.
93. Puglisi F., Minisini A.M., Barbone F., Intersimone D., Aprile G., Puppin C., et al. Galectin-3 expression in non-small cell lung carcinoma. Cancer Lett 2004, 212(2):233-239.
94. Mathieu A., Saal I., Vuckovic A., Ransy V., Vereerstraten P., Kaltner H., et al. Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung. Modern Pathol 2005, 18(9):1264-1271.
95. Paron I., Scaloni A., Pines A., Bachi A., Liu F.T., Puppin C., et al. Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun 2003, 302(3):545-553.
96. Shibata T., Noguchi T., Takeno S., Takahashi Y., Fumoto S., Kawahara K. Impact of nuclear galectin-3 expression on histological differentiation and vascular invasion in patients with esophageal squamous cell carcinoma. Oncol Rep 2005, 13(2):235-239.
97. Lotz M.M., Andrews C.W., Korzelius C.A., Lee E.C., Steele G.D., Clarke A., et al. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci U S A 1993, 90(8):3466-3470.
98. Ellerhorst J.A., Stephens L.C., Nguyen T., Xu X.C. Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP. Prostate 2002, 50(1):64-70.
99. Takenaka Y., Fukumori T., Yoshii T., Oka N., Inohara H., Kim H.R., et al. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 2004, 24(10):4395-4406.
100. 2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 1999, 59(24):6239-6245.
101. Gaudin J.C., Mehul B., Hughes R.C. Nuclear localisation of wild type and mutant galectin-3 in transfected cells. Biol Cell 2000, 92(1):49-58.
102. Nakahara S., Hogan V., Inohara H., Raz A. Importin-mediated nuclear translocation of galectin-3. J Biol Chem 2006, 281(51):39649-39659.
103. Nakahara S., Oka N., Wang Y., Hogan V., Inohara H., Raz A. Characterization of the nuclear import pathways of galectin-3. Cancer Res 2006, 66(20):9995-10006.
104. Cowles E.A., Agrwal N., Anderson R.L., Wang J.L. Carbohydrate-binding protein 35. Isoelectric points of the polypeptide and a phosphorylated derivative. J Biol Chem 1990, 265(29):17706-17712.
105. Huflejt M.E., Turck C.W., Lindstedt R., Barondes S.H., Leffler H. L-29, a soluble lactose-binding lectin, is phosphorylated on serine 6 and serine 12 in vivo and by casein kinase I. J Biol Chem 1993, 268(35):26712-26718.
106. Tsay Y.G., Lin N.Y., Voss P.G., Patterson R.J., Wang J.L. Export of galectin-3 from nuclei of digitonin-permeabilized mouse 3T3 fibroblasts. Exp Cell Res 1999, 252(2):250-261.
107. Yang R.Y., Hill P.N., Hsu D.K., Liu F.T. Role of the carboxyl-terminal lectin domain in self-association of galectin-3. Biochemistry 1998, 37(12):4086-4092.
108. Ahmad N., Gabius H.J., Andre S., Kaltner H., Sabesan S., Roy R., et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem 2004, 279(12):10841-10847.
109. Shaulsky G., Goldfinger N., Ben-Ze'ev A., Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 1990, 10(12):6565-6577.
110. Fabbro M., Henderson B.R. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 2003, 282(2):59-69.
111. Chen M.H., Ben-Efraim I., Mitrousis G., Walker-Kopp N., Sims P.J., Cingolani G. Phospholipid scramblase 1 contains a nonclassical nuclear localization signal with unique binding site in importin alpha. J Biol Chem 2005, 280(11):10599-10606.
112. Funasaka T., Balan V., Raz A., Wong R.W. Nucleoporin Nup98 mediates galectin-3 nuclear-cytoplasmic trafficking. Biochem Biophys Res Commun 2013, 434(1):155-161.
113. Nangia-Makker P., Balan V., Raz A. Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron 2008, 1(1):43-51.
114. Haudek K.C., Spronk K.J., Voss P.G., Patterson R.J., Wang J.L., Arnoys E.J. Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim Biophys Acta 2010, 1800(2):181-189.
115. Aberle H., Bauer A., Stappert J., Kispert A., Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997, 16(13):3797-3804.
116. Ikeda S., Kishida S., Yamamoto H., Murai H., Koyama S., Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998, 17(5):1371-1384.
117. Kishida S., Yamamoto H., Ikeda S., Kishida M., Sakamoto I., Koyama S., et al. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem 1998, 273(18):10823-10826.
118. Hart M.J., de los Santos R., Albert I.N., Rubinfeld B., Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 1998, 8(10):573-581.
119. Itoh K., Krupnik V.E., Sokol S.Y. Axis determination in Xenopus involves biochemical interactions of axin, glycogen synthase kinase 3 and beta-catenin. Curr Biol 1998, 8(10):591-594.
120. Sakanaka C., Weiss J.B., Williams L.T. Bridging of beta-catenin and glycogen synthase kinase-3beta by axin and inhibition of beta-catenin-mediated transcription. Proc Natl Acad Sci U S A 1998, 95(6):3020-3023.
121. Polakis P. Wnt signaling and cancer. Genes Dev 2000, 14(15):1837-1851.
122. Kitagawa M., Hatakeyama S., Shirane M., Matsumoto M., Ishida N., Hattori K., et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J 1999, 18(9):2401-2410.
123. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., et al. Identification of c-MYC as a target of the APC pathway. Science 1998, 281(5382):1509-1512.
124. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999, 96(10):5522-5527.
125. Crawford H.C., Fingleton B.M., Rudolph-Owen L.A., Goss K.J., Rubinfeld B., Polakis P., et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999, 18(18):2883-2891.
126. Koh T.J., Bulitta C.J., Fleming J.V., Dockray G.J., Varro A., Wang T.C. Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest 2000, 106(4):533-539.
127. Kolligs F.T., Nieman M.T., Winer I., Hu G., Van Mater D., Feng Y., et al. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell 2002, 1(2):145-155.
128. Araki Y., Okamura S., Hussain S.P., Nagashima M., He P., Shiseki M., et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003, 63(3):728-734.
129. Giles R.H., van Es J.H., Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003, 1653(1):1-24.
130. Lu Z., Hunter T. Wnt-independent beta-catenin transactivation in tumor development. Cell Cycle 2004, 3(5):571-573.
131. Shimura T., Takenaka Y., Fukumori T., Tsutsumi S., Okada K., Hogan V., et al. Implication of galectin-3 in Wnt signaling. Cancer Res 2005, 65(9):3535-3537.
132. Mazurek N., Conklin J., Byrd J.C., Raz A., Bresalier R.S. Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligands. J Biol Chem 2000, 275(46):36311-36315.
133. Shi Y., He B., Kuchenbecker K.M., You L., Xu Z., Mikami I., et al. Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells. Int J Cancer 2007, 121(6):1175-1181.
134. Song S., Mazurek N., Liu C., Sun Y., Ding Q.Q., Liu K., et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res 2009, 69(4):1343-1349.
135. Mendonca D.F., Chammas R., Liu F.T., Nonogaki S., Cardoso S.V., Loyola A.M., et al. The inactive form of glycogen synthase kinase-3beta is associated with the development of carcinomas in galectin-3 wild-type mice, but not in galectin-3-deficient mice. Int J Clin Exp Pathol 2012, 5(6):547-554.
136. Ferrazzo K.L., Neto M.M., dos Santos E., dos Santos Pinto D., de Sousa S.O. Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. J Oral Pathol Med 2009, 38(9):701-707.
137. Kim S.J., Shin J.Y., Cheong T.C., Choi I.J., Lee Y.S., Park S.H., et al. Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of beta-catenin in gastric cancer. Clin Exp Metastasis 2011, 28(8):743-750.
138. Balan V., Nangia-Makker P., Schwartz A.G., Jung Y.S., Tait L., Hogan V., et al. Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res 2008, 68(24):10045-10050.
139. Braeuer R.R., Shoshan E., Kamiya T., Bar-Eli M. The sweet and bitter sides of galectins in melanoma progression. Pigment Cell Melanoma Res 2012, 25(5):592-601.
140. Fukumori T., Kanayama H.O., Raz A. The role of galectin-3 in cancer drug resistance. Drug Resist Updat 2007, 10(3):101-108.
141. Harazono Y., Nakajima K., Raz A. Why anti-Bcl-2 clinical trials fail: a solution. Cancer Metastasis Rev 2013.
142. Turner J.G., Dawson J., Sullivan D.M. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012, 83(8):1021-1032.
143. Cheng Y.L., Huang W.C., Chen C.L., Tsai C.C., Wang C.Y., Chiu W.H., et al. Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli. Biochem Biophys Res Commun 2011, 412(2):334-340.
144. Mazurek N., Byrd J.C., Sun Y., Hafley M., Ramirez K., Burks J., et al. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differentiation 2012, 19(3):523-533.
145. Kobayashi T., Shimura T., Yajima T., Kubo N., Araki K., Tsutsumi S., et al. Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of beta-catenin. Int J Cancer 2011, 129(12):2775-2786.
146. Kobayashi T., Shimura T., Yajima T., Kubo N., Araki K., Wada W., et al. Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells. Clin Exp Metastasis 2011, 28(4):367-376.
147. Lin C.I., Whang E.E., Abramson M.A., Donner D.B., Bertagnolli M.M., Moore F.D., et al. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun 2009, 379(2):626-631.
148. Lin C.I., Whang E.E., Donner D.B., Jiang X., Price B.D., Carothers A.M., et al. Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res 2009, 7(10):1655-1662.
149. Yamamoto-Sugitani M., Kuroda J., Ashihara E., Nagoshi H., Kobayashi T., Matsumoto Y., et al. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci U S A 2011, 17468-17473.
150. Rebucci M., Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 2013, 85(9):1219-1226.
151. Glinsky V.V., Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydrate Res 2009, 344(14):1788-1791.
152. Inohara H., Raz A. Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 1994, 11(6):527-532.
153. Nangia-Makker P., Hogan V., Honjo Y., Baccarini S., Tait L., Bresalier R., et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 2002, 94(24):1854-1862.
154. Platt D., Raz A. Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst 1992, 84(6):438-442.
155. Johnson K.D., Glinskii O.V., Mossine V.V., Turk J.R., Mawhinney T.P., Anthony D.C., et al. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia 2007, 9(8):662-670.
156. Wang Y., Nangia-Makker P., Balan V., Hogan V., Raz A. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death Dis 2010, 1:e101.
157. Chauhan D., Li G., Podar K., Hideshima T., Neri P., He D., et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 2005, 65(18):8350-8358.
158. Lee Y.K., Lin T.H., Chang C.F., Lo Y.L. Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via beta-catenin/GSK-3beta modulation in colorectal carcinoma. PLoS One 2013, 8(11):e82478.